Oxford Textbook of Rheumatoid Arthritis最新文献

Combination therapy in rheumatoid arthritis 类风湿关节炎的联合治疗

Oxford Textbook of Rheumatoid Arthritis Pub Date : 2020-09-01 DOI: 10.1093/med/9780198831433.003.0037

B. Coumbe, E. Nikiphorou, T. Sokka-Isler

引用次数: 0

European biologics registers 欧洲生物制品注册

Oxford Textbook of Rheumatoid Arthritis Pub Date : 2020-09-01 DOI: 10.1093/med/9780198831433.003.0044

A. Zink, A. Strangfeld

引用次数: 0

Clinical recommendations 临床建议

Oxford Textbook of Rheumatoid Arthritis Pub Date : 2020-09-01 DOI: 10.1093/med/9780198831433.003.0043

A. Aga, E. Haavardsholm, T. Uhlig, T. Kvien

{"title":"Clinical recommendations","authors":"A. Aga, E. Haavardsholm, T. Uhlig, T. Kvien","doi":"10.1093/med/9780198831433.003.0043","DOIUrl":"https://doi.org/10.1093/med/9780198831433.003.0043","url":null,"abstract":"This chapter will review the most important recommendations that are relevant for evidence-based clinical practice. The main focus will be on recommendations that are specific to rheumatoid arthritis (RA) but some recommendation on special topics (e.g. biosimilars) will also be addressed. The literature to support evidence-based medicine is enormous, but the scientific quality may differ across studies. Recommendations based on systematic literature research may support evidence-based practice. Both the American College of Rheumatology (ACR) and the European League Against Rheumatism (EULAR) have published several important evidence-based recommendations. Further, task forces independent of these organizations have also presented important recommendations to support best practice. New treatment strategies have also improved RA care to an extent where remission has become an achievable goal for the majority of patients with RA. Important principles in the new treatment strategies are ‘window of opportunity’ which imply early initiation of disease-modifying antirheumatic drugs (DMARDs) before the onset of damage, and further ‘treat-to-target’ which is a strategy for follow-up with focus on reaching a predefined target, and where DMARD treatment is adjusted if the target is not achieved. Patients with early disease are monitored with ‘tight controls’, and with use of composite disease activity measures that includes joint counts.","PeriodicalId":135409,"journal":{"name":"Oxford Textbook of Rheumatoid Arthritis","volume":"1 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2020-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"129631938","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 39

Fatigue 乏力

Oxford Textbook of Rheumatoid Arthritis Pub Date : 2020-09-01 DOI: 10.1093/med/9780198831433.003.0021

E. Dures, N. Basu

{"title":"Fatigue","authors":"E. Dures, N. Basu","doi":"10.1093/med/9780198831433.003.0021","DOIUrl":"https://doi.org/10.1093/med/9780198831433.003.0021","url":null,"abstract":"Fatigue in rheumatoid arthritis (RA) is associated with inflammation, pain, disability, sleep, depression, and health beliefs, implying complex, multicausal pathways comprising differing combinations of variables. From a patient perspective, it is a common, overwhelming, and distressing symptom. From a societal perspective, fatigue is a significant predictor of high healthcare costs and the main reason for work disability and loss. This chapter will highlight the role of patients in establishing the importance of the symptom, including the proposal that it should be measured in studies of RA whenever possible. Acknowledgement of fatigue as a patient priority is a relatively recent development, and highlights the value of collaborating with patients in shaping the research agenda. There will be discussion of the scale of fatigue in RA, including data on prevalence and descriptions of its nature and impact. Research has established the unpredictable and unearned nature of RA-related fatigue with its physical, cognitive, and emotional components, and identified the associated individual and societal burden. This will be followed by conceptual models informing our understanding of the biology of rheumatoid arthritis-related fatigue, the role of bioinformatics, and the challenges of unravelling the mechanisms of this multidimensional symptom. Finally, the evidence for interventions and treatments to alleviate fatigue will be presented, with a focus on non-pharmacological approaches to support fatigue self-management.","PeriodicalId":135409,"journal":{"name":"Oxford Textbook of Rheumatoid Arthritis","volume":"22 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2020-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"131719374","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Genetics and epigenetics of rheumatoid arthritis 类风湿关节炎的遗传学和表观遗传学

Oxford Textbook of Rheumatoid Arthritis Pub Date : 2020-09-01 DOI: 10.1093/med/9780198831433.003.0005

A. Barton

引用次数: 1

Physical activity and exercise 体育活动和锻炼

Oxford Textbook of Rheumatoid Arthritis Pub Date : 2020-09-01 DOI: 10.1093/med/9780198831433.003.0024

L. Bearne, C. Opava

引用次数: 0

Biosimilars 生物仿制药

Oxford Textbook of Rheumatoid Arthritis Pub Date : 2020-09-01 DOI: 10.1002/9781118532331.ch38

V. Strand, J. Kaine, J. Isaacs

{"title":"Biosimilars","authors":"V. Strand, J. Kaine, J. Isaacs","doi":"10.1002/9781118532331.ch38","DOIUrl":"https://doi.org/10.1002/9781118532331.ch38","url":null,"abstract":"Biologic therapy for treatment of rheumatoid arthritis (RA) has evolved considerably over the past 20 years. Biosimilar development continues to accelerate at a frenetic pace worldwide. Initial regulatory efforts were developed within the EU and subsequent guidelines have now evolved in over 20 countries. Biosimilars by definition are highly similar, with ‘comparable quality, safety, and efficacy’ (EMA) and ‘no clinically meaningful differences in safety, purity, and potency’ (FDA) to the reference product. Development and manufacturing are based on reverse engineering of the reference product as only the primary amino acid sequence is known. Testing of primary, secondary, tertiary, and quaternary structure, binding pharmacokinetics, and stability is required. Characterization of post-translational modifications and biologic function, pharmacokinetics, evaluation of immunogenicity, and at least one comparative efficacy clinical trial are major requirements for regulatory approval. Clinical trials to assess biosimilarity are required in only one clinical indication and may be extrapolated to other indications for which the reference product is approved. Both single and multiple switching trials (between biosimilar and reference product) have yielded consistent results across numerous patient populations and diseases, with no evidence of detrimental outcomes. Two prospective large observational series (Danbio and Nor-Switch) have similarly assessed non-medical switching. Several open-label switching studies have revealed equivalent efficacy, safety, and discontinuation rates but real-world studies have raised concerns about potential nocebo responses.","PeriodicalId":135409,"journal":{"name":"Oxford Textbook of Rheumatoid Arthritis","volume":"4 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2020-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"133802631","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Occupational therapy 职业治疗

Oxford Textbook of Rheumatoid Arthritis Pub Date : 2020-09-01 DOI: 10.1093/med/9780198831433.003.0026

A. Hammond, Joanne Adams, Yeliz Prior

引用次数: 0

Foot health 脚的健康

Oxford Textbook of Rheumatoid Arthritis Pub Date : 2020-09-01 DOI: 10.1093/med/9780198831433.003.0025

H. Siddle, A. Redmond

引用次数: 0

Ultrasound in rheumatoid arthritis 类风湿关节炎的超声诊断

Oxford Textbook of Rheumatoid Arthritis Pub Date : 2020-09-01 DOI: 10.1093/med/9780198831433.003.0018

A. Filer, M. D’Agostino, I. Sahbudin

引用次数: 0